Clinical Trial Update: Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating inotuzumab ozogamicin for patients with acute lymphoblastic leukemia who remain MRD-positive after hematopoietic stem cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

Sponsor: Sheng-Li Xue, MD | Conditions: ALL, MRD-positive | Phase 2 | Status: RECRUITING